bioMérieux has created a new Fungal Susceptibility Card for susceptibility testing of Candida species and Cryptococcus neoformans.
The VITEK 2 ASTYS07 card includes a sixth antifungal agent, micafungin, providing a valuable enhancement to antifungal susceptibility testing.
Yeast infections have become a major cause of morbidity and mortality in at-risk patient populations.
Early diagnosis and prompt treatment are the key to achieving successful outcomes in these infections, and bioMérieux’s VITEK 2 instrument offers automated, standardized and rapid yeast susceptibility testing.
The VITEK 2 AST-YS07 Fungal Susceptibility Card, which replaces VITEK 2 AST-YS06, complements the current antifungals - amphotericin B, caspofungin, fluconazole, flucytosine and voriconazole - with micafungin, an echinocandin active against Candida species, further extending the capabilities of the VITEK 2 and helping to ensure that the correct treatment is swiftly initiated.